Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Paradigm Biopharmaceuticals ( (AU:PAR) ) just unveiled an announcement.
Paradigm Biopharmaceuticals Limited has announced the quotation of 11,714,207 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 8, 2025. This move is part of the company’s strategic efforts to enhance its financial flexibility and support its ongoing development projects, potentially strengthening its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for treating inflammatory diseases. The company is primarily engaged in creating solutions that address unmet medical needs, with a market focus on innovative treatments for conditions such as osteoarthritis and other musculoskeletal disorders.
Average Trading Volume: 899,644
Technical Sentiment Signal: Hold
Current Market Cap: A$144.1M
Find detailed analytics on PAR stock on TipRanks’ Stock Analysis page.